Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial to Reduce Cardiovascular Events with Aranesp Therapy
2004-000134-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anaemia and chronic kidney disease (CKD) comparing Aranesp with Placebo/control (2 arms). Started Aug 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2004-000134-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000134-37.